A Multicenter, Open-Label, Single-Arm, Two-Stage Study of the Efficacy and Safety of AVE0005 (VEGF Trap) Administered Intravenously Every 2 Weeks in Patients With Platinum- and Erlotinib-Resistant Locally Advanced or Metastatic Non-Small-Cell-Lung Adenocarcinoma.

Trial Profile

A Multicenter, Open-Label, Single-Arm, Two-Stage Study of the Efficacy and Safety of AVE0005 (VEGF Trap) Administered Intravenously Every 2 Weeks in Patients With Platinum- and Erlotinib-Resistant Locally Advanced or Metastatic Non-Small-Cell-Lung Adenocarcinoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Dec 2012

At a glance

  • Drugs Aflibercept (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Sanofi
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 22 Jun 2012 Inclusion and exclusion criteria amended as reported by European Clinical Trials Database record.
    • 07 Jul 2009 Actual end date (Mar 2008) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top